Table 3.

Characterization of patients positive for CTCs in pre-treatment (n=21)

Patient number	Gender	Age	TNM grouping	Histologic diagnosis	Metastasis sites	Treatment	Number of CTCs in TSF
1	Male	74	III	Clear-cell	—	Nephrectomy	4
2	Male	32	IV	Clear-cell	Lung, adrenal gland	Metastasectomy, targeted therapy	1
3	Male	67	III	Clear-cell	—	Nephrectomy	1
4	Female	70	IV	Chromophobe	Lymph nodes	Nephrectomy	3
5	Male	61	IV	Clear-cell	Lung	Nephrectomy, targeted therapy	2
6	Female	70	IV	Clear-cell	Lymph node, lung, pelvic mass	Nephrectomy, targeted therapy	1
7	Male	61	III	Clear-cell	Lymph node	Nephrectomy	1
8	Male	66	III	Clear-cell	—	Nephrectomy	1
9	Male	53	IV	Clear-cell	Lung, psoas muscle	Nephrectomy, targeted therapy	3
10	Female	62	III	Clear-cell	—	Nephrectomy	1
11	Male	58	III	Clear-cell	—	Nephrectomy	3
12	Male	67	IV	Clear-cell, papillary	Lymph node, bone, liver	Nephrectomy, targeted therapy	1
13	Male	47	IV	Clear-cell	Adrenal gland	Metastasectomy	2
14	Male	70	IV	Clear-cell with sarcomatoid component	Lymph nodes, lung	Nephrectomy, targeted therapy	6
15	Male	67	III	Clear-cell	—	Nephrectomy, targeted therapy	5
16	Female	77	IV	Clear-cell	Lymph nodes, lung	Targeted therapy	3
17	Female	67	IV	Clear-cell	Lung	Nephrectomy	5
18	Male	58	IV	Clear-cell	Lung, adrenal gland	Metastasectomy, targeted therapy	2
19	Male	40	IV	Clear-cell	Lung	Nephrectomy, targeted therapy	1
20	Female	53	IV	Clear-cell	Lung, liver	Nephrectomy, targeted therapy	1
21	Female	51	III	Clear-cell	—	Nephrectomy	1

CTCs: circulating tumor cells; TNM: tumor-node-metastasis; TSF: tapered-slit filter.